EA200401160A1 - Производные тиазола и оксазола, которые модулируют активность ppar - Google Patents

Производные тиазола и оксазола, которые модулируют активность ppar

Info

Publication number
EA200401160A1
EA200401160A1 EA200401160A EA200401160A EA200401160A1 EA 200401160 A1 EA200401160 A1 EA 200401160A1 EA 200401160 A EA200401160 A EA 200401160A EA 200401160 A EA200401160 A EA 200401160A EA 200401160 A1 EA200401160 A1 EA 200401160A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ppar
activity
compounds
discloses
oxyazole
Prior art date
Application number
EA200401160A
Other languages
English (en)
Inventor
Ксуе-Мин Ченг
Ное Оуано Эрасга
Гари Фредерик Филзен
Эндрю Джордж Гейер
Читасе Ли
Бхарат Калидас Триведи
Original Assignee
Уорнер-Ламберт Компани Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уорнер-Ламберт Компани Ллс filed Critical Уорнер-Ламберт Компани Ллс
Publication of EA200401160A1 publication Critical patent/EA200401160A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Данное изобретение раскрывает соединения, которые изменяют активность PPAR. Также изобретение раскрывает фармацевтически приемлемые соли соединений, фармацевтически приемлемые композиции, содержащие эти соединения или их соли, и способы применения их в качестве терапевтических агентов для лечения или предупреждения гиперлипидемии и гиперхолестеринемии у млекопитающих. Настоящее изобретение также раскрывает способ получения описываемых соединений.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401160A 2002-03-07 2003-03-03 Производные тиазола и оксазола, которые модулируют активность ppar EA200401160A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36240002P 2002-03-07 2002-03-07
PCT/IB2003/000817 WO2003074052A1 (en) 2002-03-07 2003-03-03 Thiazole and oxazole derivatives that modulate ppar activity

Publications (1)

Publication Number Publication Date
EA200401160A1 true EA200401160A1 (ru) 2005-02-24

Family

ID=27789156

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401160A EA200401160A1 (ru) 2002-03-07 2003-03-03 Производные тиазола и оксазола, которые модулируют активность ppar

Country Status (29)

Country Link
US (1) US6833380B2 (ru)
EP (1) EP1485091A1 (ru)
JP (1) JP2005524665A (ru)
KR (1) KR20040091694A (ru)
CN (1) CN1638768A (ru)
AP (1) AP2004003123A0 (ru)
AR (1) AR038883A1 (ru)
AU (1) AU2003207891A1 (ru)
BR (1) BR0308221A (ru)
CA (1) CA2476580A1 (ru)
CO (1) CO5601013A2 (ru)
EA (1) EA200401160A1 (ru)
EC (1) ECSP045275A (ru)
GT (1) GT200300053A (ru)
HR (1) HRP20040810A2 (ru)
IL (1) IL163768A0 (ru)
IS (1) IS7399A (ru)
MA (1) MA27182A1 (ru)
MX (1) MXPA04008624A (ru)
NO (1) NO20044245L (ru)
OA (1) OA12781A (ru)
PA (1) PA8568701A1 (ru)
PE (1) PE20031010A1 (ru)
PL (1) PL372971A1 (ru)
TN (1) TNSN04167A1 (ru)
TW (1) TW200400027A (ru)
UY (1) UY27704A1 (ru)
WO (1) WO2003074052A1 (ru)
ZA (1) ZA200406491B (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
JP2007536343A (ja) 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
EP1751120A4 (en) * 2004-05-25 2010-05-05 Metabolex Inc SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND MANUFACTURING METHOD THEREFOR
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
CA2631390C (en) 2005-12-22 2014-03-11 Per Sauerberg Phenoxy acetic acids as ppar delta activators
EP1999098A2 (en) 2006-03-09 2008-12-10 High Point Pharmaceuticals, LLC Compounds that modulate ppar activity, their preparation and use
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CN101801951B (zh) 2007-09-14 2013-11-13 杨森制药有限公司 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮
EP2200985B1 (en) 2007-09-14 2011-07-13 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
US8691813B2 (en) 2008-11-28 2014-04-08 Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ME01573B (me) 2009-05-12 2014-09-20 Addex Pharma Sa DERIVATI 1,2,4-TRIAZOLO[4,3-a]PIRIDINA I NJIHOVA UPOTREBA U TRETMANU ILI PREVENCIJI NEUROLOŠKIH I PSIHIJATRIJSKIH POREMEĆAJA
MX2011011962A (es) 2009-05-12 2012-02-28 Janssen Pharmaceuticals Inc Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores de glutamato metabotropico (mglur2).
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
AU2011328195B2 (en) 2010-11-08 2015-04-02 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
EP3043789B1 (en) 2013-09-09 2020-07-08 vTv Therapeutics LLC Use of a ppar-delta agonists for treating muscle atrophy
PL3096790T3 (pl) 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2194179T3 (es) 1996-02-02 2003-11-16 Merck & Co Inc Derivados heterociclicos como agentes antidiabeticos y antiobesidad.
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
CN1233241A (zh) 1996-08-19 1999-10-27 日本烟草产业株式会社 丙酸衍生物及其用途
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DK1206457T3 (da) 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
EP1313716B1 (en) 2000-08-23 2007-05-02 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
EP1313715B1 (en) 2000-08-23 2007-08-01 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
JP2004517100A (ja) 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
JP4279137B2 (ja) 2001-05-29 2009-06-17 京都薬品工業株式会社 新規複素環誘導体およびその医薬用途
ES2275887T3 (es) 2001-06-07 2007-06-16 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisoma (ppar).
WO2002102780A1 (fr) 2001-06-18 2002-12-27 Ono Pharmaceutical Co., Ltd. Compose derive de tetrahydroquinoline et medicament contenant ledit compose comme principe actif
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
EP1435946B8 (en) 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Also Published As

Publication number Publication date
PL372971A1 (en) 2005-08-08
TNSN04167A1 (fr) 2007-03-12
BR0308221A (pt) 2005-01-04
NO20044245L (no) 2004-10-06
US6833380B2 (en) 2004-12-21
GT200300053A (es) 2003-10-10
JP2005524665A (ja) 2005-08-18
PA8568701A1 (es) 2003-11-12
AP2004003123A0 (en) 2004-09-30
KR20040091694A (ko) 2004-10-28
TW200400027A (en) 2004-01-01
MA27182A1 (fr) 2005-01-03
IL163768A0 (en) 2005-12-18
EP1485091A1 (en) 2004-12-15
AU2003207891A1 (en) 2003-09-16
ECSP045275A (es) 2004-10-26
CA2476580A1 (en) 2003-09-12
US20030207916A1 (en) 2003-11-06
HRP20040810A2 (en) 2004-12-31
AR038883A1 (es) 2005-02-02
PE20031010A1 (es) 2003-12-12
MXPA04008624A (es) 2004-12-06
IS7399A (is) 2004-08-12
WO2003074052A1 (en) 2003-09-12
UY27704A1 (es) 2003-10-31
OA12781A (en) 2006-07-07
CN1638768A (zh) 2005-07-13
ZA200406491B (en) 2006-05-31
CO5601013A2 (es) 2006-01-31

Similar Documents

Publication Publication Date Title
EA200401160A1 (ru) Производные тиазола и оксазола, которые модулируют активность ppar
EA200400943A1 (ru) Тиазольные и оксазольные производные, которые модулируют ppar активность
EA200401153A1 (ru) Соединения, модулирующие активность ppar, и способы их получения
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
EA200500488A1 (ru) Фармацевтические составы модафинила
EA200500814A1 (ru) Производные пирролопиримидина
EA200300919A1 (ru) N-замещенные неарильные гетероциклические антагонисты nmda/nr2b
EA200801041A1 (ru) Ингибиторы мек и способы их применения
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
ATE440603T1 (de) 8-hydroxychinolinderivate
EA199800909A1 (ru) Тригидрат мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)пиперазин-1-ил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, фармацевтическая композиция и способ лечения психического расстройства
EA200301142A1 (ru) Производные гетероциклилокси-, -тиокси- и -аминобензазола в качестве лигандов 5-гидрокситриптамина-6
BR0308202A (pt) Tiazóis e oxazóis substituìdos que modulam a atividade de ppar
EA200300829A1 (ru) Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6
EA200501658A2 (ru) Производные азаспироалканов в качестве ингибиторов металлопротеаз
EA199900421A1 (ru) Бензонафтиридины в качестве бронхиальных терапевтических средств
DK0687176T3 (da) Anvendelse af riluzol til behandling af AIDS-relaterede nervesygdomme
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
HK1094307A1 (en) Use of pyrrole derivatives to combat anxiety
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
EA199900689A1 (ru) Атропизомеры 3-гетероарил-4(3h)-хиназолинонов для лечения нейродегенеративных и связанных с травмами цнс состояний
EA200100930A1 (ru) Способ лечения хозл
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
DK1353660T3 (da) Anvendelse af substituerede 6-dimethylaminomethyl-1-phenylcyclohexanforbindelser til behandling af urininkontinens